Partnerships
The partnership between KWS BioTest and Quotient Bioresearch enables the two companies to provide high quality screening of anti-infectives all the way from in vitro activity assays, efficacy and resistance profiling through validated models of human disease to clinical investigations, with full scientific support.
Quotient is a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide. Their innovative range of services are provided on a standalone basis, or integrated, to deliver bespoke development programmes.
To find out more visit their website via the link below:
The expertise provided by KWS BioTest in the design and implementation of experimental autoimmune encephalomyelitis (EAE) disease models, of the human demyelinating condition multiple sclerosis (MS), has been complemented in an agreement with Solupharm Limited UK.
Founded in 1999 by Director, Dr. Chris Bolton, Solupharm provides consultancy services dedicated to the use of EAE models in the search for MS therapies. Dr. Bolton provides a combination of academic expertise coupled with an appreciation of the pharmaceutical industry’s requirements for drug discovery in the field of in vivo models of MS.
Dr. Bolton comments ''I am very pleased to have formed a partnership with KWS BioTest who offer an impressive range of in vivo disease models for use in establishing drug efficacy. In particular KWS BioTest are one of the few CRO's to offer a true model of chronic relapsing-remitting EAE, featuring clear episodes of neurological deficit followed by definitive periods of disease remission, together with demyelination and axonal disruption. The EAE models, skills and expertise now available through the joint venture are comprehensive and combine a wealth of knowledge in the design, implementation and interpretation of studies'.
KWS founder and CSO, Professor Neil Williams, comments ‘Dr. Bolton has a proven, long-standing record in the theoretical and practical aspects of EAE which complements perfectly our own knowledge and pharmacology services in this area. KWS will continue to provide high quality in vivo models of acute, chronic and remitting/relapsing EAE to new and existing customers. Our partnership will enable existing Solupharm clients, as well as clients of KWS, access to Dr Bolton's expertise and to his direct supervision of their studies, with the additional benefit that all the work at KWS being carried out at our ISO9001 accredited facilities’.
For further information please visit: